Pharma Journalist -

Astro's Interpretation of the Phase II CONDOR trial suggests that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic…
Read More...

Astro indicates positive results of  phase II OPTIMA Clinical Trial signifying that patients with head and neck cancers associated with the human papillomavirus (HPV), including those…
Read More...

Cytobank and the U.S Food and Drug Administration collaborate to develop machine learning-based methods for characterizing the morphology of multipotent mesenchymal stromal cells…
Read More...

Quidel Corporation who is known for providing diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, sought 510 (k) Clearance from the United…
Read More...

Degenerative disc disease has long been considered an inseparable part of aging but new breakthrough research from SpinalCyte suggests a new cell-based therapy could provide a cure for…
Read More...

Biopharmaceutical company MOLOGEN AG declared having signed a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for its…
Read More...

In a bid to treat metastatic radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC), Exelixis declared results from a Phase 2 Investigator-sponsored trial of cabozantinib.…
Read More...

Merck declared that it will rescind protocol 019 also termed as the APECS study assessing verubecestat (MK-8931), an investigational small molecule inhibitor of the beta-site amyloid…
Read More...

European Commission extends approval to Celltrion's Herzuma for treatment of patients with early breast Cancer, metastatic breast cancer or metastatic gastric cancer whose tumors have…
Read More...

Strong biologics, biosimilars and injectable drug-delivery device pipelines for pharma companies coupled with the increased workload in producing these and increasing trends in…
Read More...